Posted by Michael Wonder on 28 Jun 2022
Apnimed granted FDA fast track designation for AD109, a novel first in class oral pharmacologic combination for the treatment of obstructive sleep apnoea
28 June 2022 - Additional Phase 2b data evaluating AD109 as potential treatment for obstructive sleep apnoea anticipated in Q3 2022.
Apnimed announced today that the U.S. FDA has granted fast track designation for its oral pharmacologic AD109 for the treatment of obstructive sleep apnoea.
